News

BMJ2d
Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features
Objective Antibodies against contactin-associated protein-like 2 (CASPR2-Abs) have been described in acquired neuromyotonia, limbic encephalitis (LE) and Morvan syndrome (MoS). However, it is unknown ...
BMJ9d
Early clinical surrogates for outcome prediction after stroke thrombectomy in daily clinical practice
Background and purpose To investigate early clinical surrogates for long-term independency of patients treated with thrombectomy for large vessel occlusion stroke in daily clinical routine. Methods ...
BMJ11d
Nodopathy: chronic inflammatory demyelinating polyneuropathy with anti-neurofascin 155 antibodies
Correspondence to Dr Satoshi Kuwabara, Department of Neurology, Graduate School of Medicine, Chiba University 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan; kuwabara-s{at}faculty.chiba-u.jp While ...
BMJ16d
Long-term maintenance of mycophenolate mofetil in anti-NMDA receptor encephalitis (LEARN): a multicentre, open-label, blinded-endpoint, randomised controlled trial
Background Anti-N-methyl-D-aspartate receptor encephalitis (NMDARE) is a severe autoimmune disorder with high morbidity and mortality. Current treatments have limitations including relapse, ...
BMJ16d
Biomarker-based Alzheimer’s diagnosis: learning to use p-tau217 wisely
http://orcid.org/0000-0003-3174-6027Michael P Lunn1,2 The increasing complexity of personalised medicine to deliver targeted and highly specific therapeutics to ...
BMJ17d
Relationship between motor cortical and peripheral axonal hyperexcitability in amyotrophic lateral sclerosis
Correspondence to Dr Kazumoto Shibuya, Neurology, Chiba University, Graduate School of Medicine, Chiba 260-8670, Japan; kazumoto{at}net.email.ne.jp Background Previous studies have shown that patients ...
BMJ25d
Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy
Correspondence to Dr Shigeaki Suzuki, Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan; sgsuzuki{at}z3.keio.jp Objective To elucidate ...
BMJ27d
Evolution of depressive symptoms in the 15 years preceding dementia
Background Depression has been consistently linked to the onset of dementia, but the temporality and nature of this association—whether causal, prodromal or due to shared pathophysiology—remain ...
BMJ1mon
Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled study
Correspondence to Professor Gen Sobue, Research Division of Dementia and Neurodegenerative Disease, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466 8550, Japan; ...
BMJ1mon
Cluster analysis showed long-term cognition can be predicted by looking at regional grey matter atrophy in the first two years of multiple sclerosis course
Background Grey matter (GM) atrophy is associated with cognitive impairment (CI) in multiple sclerosis (MS). We aimed to investigate the predictive role of early regional GM damage for long-term CI.
BMJ1mon
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
Background Extended interval dosing (EID) of natalizumab is a promising strategy to optimise treatment in multiple sclerosis (MS). Personalised EID by therapeutic drug monitoring can enable further ...
BMJ2mon
Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders
Disease-modifying treatments for major neurocognitive disorders, including Alzheimer’s disease, Parkinson’s disease and other cognitive deficits, are among the main unmet needs in modern medicine.